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Recurrent bacterial infection of the kidney was previously thought to be responsible for the
renal scarring typical of chronic pyelonephritis until recent studies suggested that recurrent
bacteriuria rarely produces chronic pyelonephritis in the absence of obstructive uropathy. In
contrast, the association between vesicoureteral reflux (VUR) and chronic pyelonephritis has
been observed frequently in the absence of urinary infection. Although the mechanism by which
VUR injures the kidney has not been defined, recent observations have suggested that some
component ofurine might serve as an antigenic determinant involved in the immunopathogenesis
ofrenal scarring in VUR. Therefore, the present studies investigated the immunopathogenic role
ofTamm-Horsfall protein (THP) in (1) a rabbit model oftubulointerstitial nephritis; (2) a swine
model of reflux nephropathy; and (3) patients with recurrent nephrolithiasis. The antigenic
similarities between THP and uropathic bacteria were also studied.
Our observations indicate that autoimmune responses to THP may occur after exposure to
THP by intravenous challenge in rabbits, by urinary reflux in pigs, and in recurrent nephrolithia-
sis in man. Also, extracts ofuropathic coliforms competitively inhibit the binding ofhuman THP
toitsantibody. Thesestudiessuggest that autoimmune responses toTHPmaybethepathogenetic
mechanism by which these factors, including bacteriuria, contribute to "chronic pyelonephritis."
Historically, the renal entity of "chronic atrophic pyelonephritis" emerged from a
series ofclinical and pathological observations beginning with E.L. Wagner's in 1882
[1] and extending to Weiss and Parker's in 1939 [2]. Most ofthecases were in children
and young adults who had a history ofrecurrent urinary tract infection dating back to
early childhood. In some ofthese cases, however, there was no such history ofurinary
infection, and the same observations are also true today.
Although the role of bacterial infection as the major determinant for the develop-
ment of acute pyelonephritis has been well documented for years, the nature of the
renal scarring typical of chronic "atrophic" pyelonephritis has been a matter of
controversy for at least three decades. In fact, for many years most of us were
convinced (and some may still be), that recurrent bacterial infection of the kidney is
primarily responsible for the pathologic entity of "chronic pyelonephritis." Pathologi-
cally, the term "chronic pyelonephritis" describes shrunken, irregular, coarsely scarred
kidneys with focal thinning ofthe renal parenchyma, often from an original dimension
ofthree centimeters in thickness to a final depth ofonly two millimeters [3]. However,
after almost three decades of following patients, primarily women, with recurrent
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urinary tract infections, we have learned that recurrent bacteriuria alone, that is, in the
absence of some form of obstructive uropathy, rarely, if ever, leads to chronic renal
failure and to the pathologic entity of "chronicatrophicpyelonephritis" [4,5]. During
this time, we also learned that, whereas many etiologic agents have been shown to
produce chronic tubulointerstitial damage, only a limited number of conditions can
lead to the pathologic picture ofchronic pyelonephritis [3,6]. These are: (a) vesicoure-
teral reflux [7]; (b) urinary obstruction [6]; (c) analgesic nephropathy; (d) unusual
forms of papillary necrosis which occur in association with sickle cell disease, focal
tuberculosis, or severe dehydration in infants [8]; and (e) segmental hypoplasia (the
Ask-Upmark kidney) [9]. Even though this latter entity (Ask-Upmark kidney) was
considered, initially, to bea developmentanomaly, more recentstudies suggestthat the
majority ofpatients with segmental hypoplasia havevesicoureteral reflux, and that this
condition is almost certainly part of the spectrum of reflux nephropathy [3,6,10].
Furthermore, we now know that typical pyelonephritic scarring, in the vast majority of
patients, is due to bacterial infection superimposed on an anatomic urinary tract
anomaly, urinary obstruction, or, most commonly, vesicoureteralreflux [3,6,11].
The close association between chronic pyelonephritis and vesicoureteral reflux was
first established in 1960 by Hodson and Edwards [7], and has since been confirmed by
many other observers, so that this relationship is now widely recognized. Vesicoure-
teral reflux is frequently present (about 50 percent) in adults with classic pyelone-
phritic scarring and is almost always present (more than 90 percent) in children with
this renal pathology [12,13,14]. Furthermore, in a significant proportion of cases,
vesicoureteral reflux-associated scarring will ultimately progress to end-stage renal
disease requiring dialysis or transplantation [3,6,14]. In some centers, from 15 to 20
percent ofadults under 50 years ofage and more than 30 percent ofchildren requiring
renal substitution have this diagnosis [3,6]. Two additional points should be empha-
sized. First, the term "reflux nephropathy," introduced by Bailey in 1973 [11], has
now replaced the term chronic pyelonephritis, for reflux-associated renal scarring.
Second, reflux nephropathy, in the absence of urinary tract infection, has been
observed to progress to severe (end-stage) renal scarring in children [11,15,16,17] and
in experimental animal models of reflux [18,19]. In fact, of those patients with renal
failure resulting from reflux nephropathy, only 60 percent have a history of urinary
tract infection [3]. It is the latter observation, namely, that the renal scarring
associated with refluxnephropathy can occur in the absenceofinfection, that has led to
much of the controversy about the pathogenesis of these lesions. Thus, the role of
infection in reflux nephropathy has been debated frequently. Although there is a
history of recurrent urinary tract infection in most children with this disease, others
present early in adult life with gross reflux, severe renal damage, and no history of
urinary tract infection [3]. What is the relationship, then, of reflux, infection, and
renal scarring? The following observations by various investigators are pertinent.
1. Vesicoureteral reflux is present in 30 to 50 percent of children with recurrent
urinary tract infection and is the most common abnormality associated with infection
regardless ofwhether the children are symptomatic or asymptomatic [20,21,22].
2. Vesicoureteral reflux is present in more than 90 percent of children with
pyelonephritic scarring, but not all children with vesicoureteral reflux (only 30 to 60
percent) go on to develop renal scars [13,22].
3. Pyelonephritic scarring is also seen in 25 percent of children with urinary tract
infection, particularly those with recurrent symptomatic bacteriuria [23-32].
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These findings, however do not explain the mechanism by which vesicoureteral
reflux injures the kidney. Subsequently, a series of observations led to the suggestion
that some normal component ofurine might serve as an antigenic determinant involved
in the immunopathogenesis of renal scarring in vesicoureteral reflux. Specifically, (1)
intrarenal reflux (IRR) was observed in some patients, mostly in children less than five
years of age, who had the more severe grades of vesicoureteral reflux [33-38]; (2)
intrarenal reflux occurred primarily in the polar regions of the kidney and was
associated with focal renal scarring, i.e., typical reflux nephropathy [3,6,39]; (3) the
polar distribution of intrarenal reflux was shown, both in children and in pigs, to be
related to differences in the orifices ofthe ducts ofBellini, e.g., slit-like in simple single
papillae, which are relatively resistant to intrarenal reflux, but wide openings in central
depressions of compound papillae which occur commonly in the polar regions (about
75 percent ofhuman kidneys have at least one compound papilla) [40-42]; (4) a direct
relationship was observed between age and the pressure required to produce intrarenal
reflux in human kidneys, i.e., lower pressures are required to produce intrarenal reflux
in kidneys from younger children [6,43]; and (5) the observation that normal urinary
proteins, particularly Tamm-Horsfall protein, could be detected in the renal intersti-
tium [44,45], renal veins and lymphatics [46,47], and peri-renal lymph nodes [48,49]
in association with intrarenal reflux. Thus, these observations suggested that some
normal component of urine might serve as an antigenic determinant involved in the
immunopathogenesis of renal scarring in vesicoureteral reflux or in other acquired
states which produce retrograde urine flow. An immunopathologic response to such an
antigen might help explain why the histologic lesions of reflux nephropathy, chronic
pyelonephritis, or chronic tubulointerstitial nephritis are characterized by mononu-
clear cellular infiltrates and fibrosis rather than polymorphonuclear leukocytes.
Furthermore, such antigenic substances, or immune responses to them, might serve as
non-invasive markers of vesicoureteral reflux and have the potential to detect those
patients at risk for reflux nephropathy and renal scarring which may ultimately lead to
end-stage renal disease. For these reasons, the normal urinary protein, Tamm-Horsfall
protein (THP), was investigated in an attempt to determine what role, ifany, it played
in the pathogenesis ofthe renal scarring, i.e., chronic pyelonephritis, observed in those
patients with sterile vesicoureteral reflux. Tamm-Horsfall protein is synthesized in the
tubular epithelial cells of the thick ascending limb of the loop of Henle and the distal
convoluted tubules, where, under normal conditions, it adheres to the luminal surface
[50-54]. Tamm-Horsfall protein is secreted into the urine in quantities of approxi-
mately 25 ,ug/ml and has not been conclusivelydemonstratedelsewhere in the body. Its
exact physiologic function is unknown, although it may influence the water permeabil-
ity characteristics of the loop of Henle [55] and, conceivably, might protect urinary
tract mucosa from the effects ofbacteria [55,56] or viruses [50,51].
A pathophysiologic role for Tamm-Horsfall protein in the development of pyelo-
nephritic scarring associated with reflux has been suggested by several clinical and
experimental observations. Interstitial deposits of Tamm-Horsfall protein have been
detected in approximately 50 percent of patients with medullary cystic disease,
approximately 30 percent of 100 human kidneys from patients with "chronic pyelo-
nephritis," reflux nephropathy, or obstructive uropathy, as compared with less than 2
percent of patients with glomerulonephritis [44-46]. Although these Tamm-Horsfall
protein deposits appear to have come from adjacent ruptured tubules, the amorphous
Tamm-Horsfall protein is frequently surrounded by focal mononuclear cell infiltrates.
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Also, acute ureteral obstruction in mice [57], rats [58], and swine [59] produces
extravasated interstitial deposits of Tamm-Horsfall protein within one to two hours.
Serologic responses (IgG) to human Tamm-Horsfall protein have been observed in
patients with recent urinary obstruction, vesicoureteral reflux, and acute pyelonephri-
tis, but notin patients withcystitis, asymptomaticbacteriuria, refluxnephropathy with
scarring, or end-stage renal disease [60-68].
The following studies from my laboratory, initiated by Dr. Robert Marier and
colleagues [60], and thereafter by Drs. Andrew Mayrer, Eric Berke, and Peggy
Miniter [68-70], were designed to investigate further the immunopathogenic role of
Tamm-Horsfall protein in a rabbit model oftubulointerstitial nephritis, and in a swine
model of reflux nephropathy. Mayrer and Miniter also examined the immune
responses toTamm-Horsfall protein in patients with recurrent nephrolithiasis, who are
at risk ofdeveloping renal damage and chronic pyelonephritis [68], and also explored
the antigenic similarities between Tamm-Horsfall protein and protein-containing
components ofuropathic bacteria [68,71].
Rabbit Model of Tubulointerstitial Nephritis One hundred twenty-one rabbits
were challenged by the intravenous route every twenty-eight days for up to 48 weeks
with one of the following sterile solutions: (1) homologous rabbit urine containing
rabbit Tamm-Horsfall protein; (2) rabbit urine selectively depleted ofTamm-Horsfall
protein; (3) autologous rabbiturinecontainingTamm-Horsfallprotein andobtainedby
bladder catheterization; or (4) purified rabbit Tamm-Horsfall protein. Unchallenged,
age-matched rabbits were used as normal controls.
The following serial studies were obtained at two- to four-week intervals: (1) renal
histopathology as determined by hematoxylin and eosin, Masson's to detect fibrosis,
periodic acid Schiff (PAS) to define distal tubular segments as well as to detect
Tamm-Horsfall protein, peroxidase-antiperoxidase immunohistochemical staining for
Tamm-Horsfall protein to identify the thick ascending limb ofthe loop of Henle, light
immunofluorescence microscopy (IFM) for determinations ofimmunoglobulin deposi-
tion using fluorescein-conjugated anti-rabbit immunoglobulins (IgG, IgM, and IgA)
raised in sheep and goats (Cappel Laboratories, Cochranville, PA), and electron
microscopy for ultrastructural examination for more precise characterization of
infiltrates, fibrosis, and localization; (2) serum IgG anti-Tamm-Horsfall protein
antibody levels by '25I-staphylococcal protein A radioimmunoassay [60]; (3) cell-
mediated immunity, using rabbit peripheral blood lymphocytes obtained by gelatin
sedimentation, Ficoll-Hypaque gradient centrifugation and nylon wool columns to
enrich for T cells, evaluated by a cytotoxicity assay and blast transformation [69]. The
cytotoxicity assay quantitates the cytotoxic effects of lymphocytes from challenged
rabbits against "innocent bystander" mouse A9 fibroblast target cells in the presence
ofa soluble protein antigen and is a specific test ofdelayed-type hypersensitivity [69].
Lymphocyte transformation was measured by tritiated thymidine uptake.
Light microscopy ofkidneysectionsdemonstrated acharacteristic focal tubulointer-
stitialnephritis at thecorticomedullaryjunction in 9 percentofrabbitschallenged with
homologous urine after two to 12 weeks, and in 83 percent after 16 to 48 weeks of
challenge. The same lesions were observed in 78 percent of rabbits challenged with
autologous urine and 79 percent challenged with purified rabbit Tamm-Horsfall
protein. Incomparison, noneoftheunchallenged controls and 7 percent (onerabbit) of
those challenged with Tamm-Horsfall protein-depleted homologous urine developed
tubulointerstitial nephritis. Tubulointerstitial nephritis developed more rapidly in
94TAMM-HORSFALL PROTEIN AND CHRONIC PYELONEPHRITIS
rabbits challenged with purified rabbit Tamm-Horsfall protein than in rabbits
challenged with homologous urine. Early lesions consisted of focal mononuclear cell
infiltrates that encircled isolated tubular segments identified as thick ascending limbs
ofthe loop ofHenle. Later lesions were more severe and contained more fibroblasts and
collagen, and more tubular atrophy, and often extended in a radial manner within
medullary rays. Immunofluorescence studies failed to demonstrate significant immu-
noglobulin deposition in any of the challenged animals [68]. Electron microscopy
studies demonstrated mononuclear cells along the thick ascending limb of the loop of
Henle and fibrosis.
Serum anti-Tamm-Horsfall protein antibody elevations (IgG) were common in
rabbits challenged with either urine or Tamm-Horsfall protein and correlated with the
finding oftubulointerstitial nephritis.
Cell-mediated immune responses toTamm-Horsfall protein were observed in approxi-
mately one-half the rabbits challenged with either urine contaning Tamm-Horsfall
protein or purified Tamm-Horsfall protein. In contrast, only three of 35 rabbits in the
two control groups (unchallenged and Tamm-Horsfall protein-depleted urine) had
cytotoxic lymphocytes. The presence of cytotoxic lymphocytes correlated with the
development of tubulointerstitial nephritis. These studies suggested that rabbit Tamm-
Horsfall protein is the major antigen in urine to which lymphocytes are sensitized, that
the effector cells are functional T lymphocytes since they are non-adherent to nylon wool
columns, and that the soluble supernatant (lymphokine) of the interaction between
antigen and effector lymphocyte is responsible for cytotoxicity.
Porcine Model ofReflux Nephropathy Twenty-one female miniature pigs under-
went cystotomy and right ureteral orifice meatotomy with placement of a non-
constricting 3- or 4-mmomega-shaped ring around the proximal urethra. Intravenous
pyelography, suprapubic aspirates ofbladder urines for cultures, serum creatinine, and
serum IgG anti-pig Tamm-Horsfall protein antibody titers as compared to baseline
control serum in the same pig were obtained at two-week intervals. In addition,
cell-mediated immunity was quantitated by lymphocyte-mediated cytotoxicity against
target fibroblasts in the presence of pig Tamm-Horsfall protein. The kinetics of the
pyelographic changes in porcine reflux nephropathy indicate that bladder dilatation
occurred after approximately one month, ureteral dilatation after 39 days, renal
insufficiency after 57 days, and renal scarring after 71 days [68]. Serum anti-
Tamm-Horsfall protein antibody titer elevations developed in association with ureteral
dilatation. Serum titers decreased in association with removal of the urethral omega
ring, which was required to reverse severe uremia. Pyelographic evidence of coarse
focal scarring occurred in 15 of 21 animals at this time. Lymphocyte-mediated
cytotoxicity was studied in pigs pre-operatively and when intravenous pyelography
demonstrated bladder dilatation only, ureteral dilatation, and hydronephrosis with
uremia. Abnormal lymphocyte cytotoxicity was seen most frequently when pigs
developed ureteral dilatation. Histopathologic examination of the kidneys demon-
strated chronic tubulointerstitial nephritis characterized by mononuclear cellular
infiltrates, often associated with interstitial Tamm-Horsfall protein deposits, and large
focal scars.
The observations that lymphocyte-mediated cytotoxicity developed (in challenged
rabbits and refluxing pigs) against susceptible target fibroblasts in the presence of
Tamm-Horsfall protein suggest that cell-mediated immunity to Tamm-Horsfall
protein plays an important role in the pathogenesis of tubulointerstitial nephritis.
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Earlier animal models of tubulointerstitial nephritis by Neilson and Phillips [72-75]
also suggest that cell-mediated immunity to renal tubular antigens plays an important
role in the pathogenesis of renal damage and fibrogenesis and that the elaboration of
soluble factors by sensitized lymphocytes is a primary mechanism ofrenal damage.
Immune Responses to Tamm-Horsfall Protein in Patients with Nephrolithia-
sis Serum IgG anti-human Tamm-Horsfall protein antibody and peripheral lympho-
cyte-mediated cytotoxicity and lymphocyte transformation in the presence of human
Tamm-Horsfall protein were determined in 49 patients attending the Yale-New
Haven Hospital Renal Stone Clinicwhoprovided informed consentfor avenipuncture.
All patients (32 men and 17 women) had recurrent nephrolithiasis. Twelve of the 49
showed elevated antibody titers to human Tamm-Horsfall protein as compared with
none of 12 normal control subjects. Those patients with elevated antibody titers, as
compared with those with normal antibody titers, had the first stone develop more
recently, and also had another more recent stone event (50 percent vs. 11 percent,
p < 0.02). Cell-mediated immunity to Tamm-Horsfall protein was studied in 24
patients, and 13 had either abnormal lymphocyte transformation or lymphocyte-
mediated cytotoxicity, whereas 11 patients had neither abnormality [68].
Relationship of Uropathic Coliforms to Human Tamm-Horsfall Protein The
potential for cross-reactivity between proteins obtained from uropathic coliforms and
human Tamm-Horsfall protein was investigated by competition inhibition radioimmu-
noassay [60,69]. In this assay, 50,l ofrabbit anti-human Tamm-Horsfall protein IgG
was adsorbed to the wells of microtiter plates and 40 ,l of test antigens plus 10 ,al of
'25I-human Tamm-Horsfall protein (50,000 cpm) were added, incubated, washed, and
counted. Test antigens included veronal buffer extracts of Escherichia coli
014:K7(L):NM, an untypable E. coli (ECY9), Klebsiella oxytoca, andStreptococcus
faecali. Extracts of Aspergilla fumigatus and Legionella pneumophilia were also
tested. Veronal extracts of E coli 014 were further fractionated on a Sephadex G-150
column, a column of DEAE-Sephacel anion exchange resin, and on a Sepharose-4B
anti-human Tamm-Horsfall protein IgG affinity column [68]. Veronal extracts and
specific fractions were characterized by polyacrylamide gel electrophoresis in the
presence of sodium dodecyl sulfate and stained with Coomassie blue. Furthermore,
unstained gels were electroblotted on to nitrocellulose paper, incubated with rabbit
antiserum to Tamm-Horsfall protein, overlaid with '25I staphylococcal protein A, and
autoradiographed [68]. Antisera raised in rabbits to Aspergillus fumigatus and
Candida albicans, as previously described [76,77], were used as negative controls. The
results of these studies indicated that non-radioactive human Tamm-Horsfall protein
was the most effective inhibitor of the binding of anti-human Tamm-Horsfall protein
antibody (IgG) to its antigen, human Tamm-Horsfall protein. Pig and rabbit Tamm-
Horsfall protein inhibited binding but at greater concentrations [68]. Crude veronal
extract ofE. coli 014, ECY9, and K. oxytoca also inhibited binding but at concentra-
tions reflecting lesser potencies. Inhibition was not due to mechanical or precipitogenic
influences by veronal extract on '25I-human Tamm-Horsfall protein. Comparable
concentrations of A.fumigatus extracts, albumin, and ribonuclease A did not inhibit
binding of '25I-human Tamm-Horsfall protein to its solid phase antibody [68].
Furthermore, the second ofthree peak fractions ofE. coli 014 veronal extract, eluted
from a column of Sephadex G-150, was found to have tenfold more competitive
inhibitory capacity than did the parent veronal extract and contained protein-
containing subunits ofless than 70,000 molecular weight. A fraction ofveronal extract
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was prepared by passage through an affinity column containing Sepharose-4B
covalently linked to anti-human Tamm-Horsfall protein (IgG). This fraction was
comparable to pig Tamm-Horsfall protein in its ability to inhibit binding between
'25I-human Tamm-Horsfall protein and its specific antibody [68]. Immunoautoradio-
graphs ofpolyacrylamide gels, electroblotted on to nitrocellulose paper, and incubated
sequentially with rabbit antiserum to human Tamm-Horsfall protein and '25I-labeled
staphylococcal protein A indicated that both veronal extract and its ion exchange
fractions exhibited three protein-containing subunits of less than 70,000 molecular
weight that are bound by anti-human Tamm-Horsfall protein antibody. Extracts ofS.
faecalis, A.fumigatus, and L. pneumophilia did not autoradiograph. Veronal extract
and its fractions did not autoradiograph after incubations with rabbit anti-Aspergillus
or anti-Candida antisera [68,711. Our results support the previous observations of
Fasth and colleagues [78] and indicate that veronal extracts of three uropathic
coliforms competitively inhibited binding of human Tamm-Horsfall protein to its
antibody, that purified fractions of E. coli 014 veronal extract obtained by column
chromatography were ten times less potent than pig and rabbit Tamm-Horsfall protein
in competition inhibition of human Tamm-Horsfall protein, that some eight protein-
containing subunits (<50,000 daltons) werefound by polyacrylamide gel electrophore-
sis of veronal extracts to correlate with Tamm-Horsfall protein inhibition, and that a
maximum ofthree electrophoretic subunits were detected by immunoautoradiography
in veronal extracts ofeach of the three uropathic coliforms examined in these studies
[68,71]. Further studies employed purified anti-Tamm-Horsfall protein antibody
conjugated tosepharose beads, thereby forming an immunoadsorption column capable
of isolating Tamm-Horsfall protein and cross-reactive antigens from solution. The
bacterial extracts, however, did not react with the affinity column. This finding
suggests that thecross-reactivity seen in theimmunoassays is caused by the interaction
between the protein extracts ofuropathic coliforms and Tamm-Horsfall protein and is
not representative of true immunologic cross-reactions for a common antibody.
Obviously, more studies are required before these apparent differences can be resolved
definitively.
In summary, evidence has been presented that vesicoureteral reflux can lead to renal
injury and scarring in the absence of infection and that autoimmune responses to
Tamm-Horsfall protein may occur after exposure to Tamm-Horsfall protein by
intravenous challenge, urinary reflux, or recurrent nephrolithiasis. This autoimmune
response to Tamm-Horsfall protein may be the pathogenetic mechanism by which
these factors, including bacteriuria, contribute to chronic pyelonephritis.
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